The Chronicle of Higher Education
News Blog
In the Comments

"Many, many years ago one of my English TA officemates noticed that a student wrote 'writhing' instead of 'writing.' We spent the rest of the afternoon inserting 'writhing' into textbook titles ('Writhing with a Purpose') and other phrases like 'technical writhing.' My favorite: 'writhing across the curriculum.'” --peg

Herding the 'Escape Goats': Contest Sends Up Epidemic of Student Howlers

Recent Posts

North Carolina A&T State Earns NSF Grant for Engineering Research

College of William and Mary Hires Interim Chief as President

Cuomo Reported to Be Planning New Student-Loan Lawsuit and Agreements

Southern Cal Deletes Muslim Scripture From Web Site Following Complaint

Palin Attended 4 Colleges in 5 Years to Earn Diploma


Most Commented This Month

Palin Attended 4 Colleges in 5 Years to Earn Diploma | 185

Professor Suspects UCLA Is Illegally Using Race in Admissions Decisions | 40

Cutthroat Competition for Textbook Sales Pits UMass Faculty Members Against Bookstore | 37

Southern Cal Deletes Muslim Scripture From Web Site Following Complaint | 31

British Publisher Will Release Controversial Novel About Muhammad's Bride | 17

By Category

Athletics
Community Colleges
Government & Politics
Information Technology
International
Money & Management
Northern Illinois
Research & Books
Short Subjects
Students
The Faculty

Blog Archives

Search

Keep Up to Date

Daily news blog: RSS  / Atom

Daily news reported by The Chronicle: RSS

Contact us

July 12, 2007

U. of Michigan Sells Patent Royalties From FluMist for as Much as $35-Million

The University of Michigan at Ann Arbor has made a deal to trade future royalties on one of its most important inventions — the technology used in the nasal-spray vaccine FluMist — for payments that could reach $35-million.

Under arrangements in the deal, announced this week, a Toronto company called Drug Royalty Inc. will pay Michigan the money, and then that company, rather than the university, will receive future royalty payments from the company that sells FluMist. The patent expires in about 10 years, university officials said. If sales of the drug are especially good, the university could make more than $35-million.

FluMist has been on the market since its maker, MedImmune Inc. of Gaithersburg, Md., won approval for it, in 2003. MedImmune was recently acquired by Astra Zeneca.

About one-third of the money will go to the inventors; the rest will go to the university, which plans to earmark most of the funds to the school of public health, where vaccine research continues to be a priority.

According to The Ann Arbor News, FluMist has been a financial success for the university, bringing in more than $1-million in royalties and an additional $18-milllion windfall when the university cashed in its stock in a company that was the original licensee of the invention. That company was acquired by MedImmune.

Upfront purchases of universities’ patent royalties are becoming increasingly common. In May, New York University executed what is believed to be the biggest such deal with another company. It sold a portion of its rights to patents underlying the drug Remicade, which is used to fight rheumatoid arthritis and several other autoimmune diseases, for $650-million. —Goldie Blumenstyk

Posted on Thursday July 12, 2007 | Permalink |